Rebecca Shatsky: One of our MOST innovative I-SPY 2 trial arms ever got accepted at ASCO2024 as an oral presentation

Rebecca Shatsky: One of our MOST innovative I-SPY 2 trial arms ever got accepted at ASCO2024 as an oral presentation

Rebecca Shatsky shared a post on X:

“Very happy to announce that 1 of our MOST innovative I-SPY 2 trial arms ever got accepted at ASCO2024 as an oral presentation. I also happen to be f1st author on this 1 . If you want to talk PERSONALIZED curative intent breast cancer therapy come hear me speak on June 3rd!

Hope to make my beloved I-SPY 2 trial team proud and spread the word about the incredible work that is being done to love the field of breast cancer therapy forward. For newly diagnosed patients, this is a trial you should learn about. There is nothing like it out there!
And for other institutions with high volume of breast cancer patients! Please consider joining the I-SPY collaborative. We are open at 30+ institutions around the country and would love to work with you!!!!”

Source: Rebecca Shatsky/X

Rebecca A. Shatsky is an Associate Professor of Medicine and a board-certified medical oncologist at the University of California, San Diego. She specializes in treating breast cancer and is part of UC San Diego Health’s Precision Immunotherapy Clinic. Dr. Shatsky is a member of the NCCN guideline panel for Genetic/High-Risk Assessment of Breast, Ovarian, and Pancreatic Cancer and the panel for the treatment of Cancer-Associated Pain. Dr. Shatsky is a well known social media influencer.

ASCO2024 breast cancer therapy cancer I-SPY 2 trial OncoDaily Oncology Rebecca Shatsky